Business Context and Reporting Period
This Form 8-K Current Report was filed by TScan Therapeutics, Inc. (TCRX) on December 7, 2023, reporting events occurring on December 6, 2023. The filing focuses on corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of R. Keith Woods to the Board of Directors, effective December 6, 2023. Key details include:
- Role: Class II Director serving until the 2025 annual meeting of stockholders.
- Independence: Determined to be an independent director under Nasdaq listing standards.
- Committee Assignments: Appointed to the Audit Committee and the Compensation Committee.
- Committee Composition:
- Audit Committee: R. Keith Woods, Katina Dorton, Gabriela Gruia, and Barbara Klencke.
- Compensation Committee: R. Keith Woods, Stephen Biggar, Katina Dorton, and Barbara Klencke.
Compensation and Governance Details
Mr. Woods will receive cash and equity compensation pursuant to the Company's non-employee director policy. Specific terms include:
- Equity Grant: An option to purchase 17,500 shares of voting common stock.
- Exercise Price: Equal to the closing market price on the date of grant.
- Vesting Schedule: Vests in full upon the earlier of the first anniversary of the grant date or the 2024 annual meeting of stockholders, subject to continued service.
- Indemnification: The Company will enter into an indemnification agreement with Mr. Woods consistent with agreements held by other directors.
The filing states there are no other arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the independence status of R. Keith Woods and his qualifications for the Audit Committee.
- Review the full text of the non-employee director compensation policy to understand cash compensation amounts not detailed in this summary.
- Confirm the closing market price of TCRX stock on December 6, 2023, to calculate the exercise price of the granted options.
- Check for any subsequent filings regarding the 2024 annual meeting of stockholders to confirm vesting timelines.